Semax vs Davunetide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: SEMAX, Heptapeptide SEMAX
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s as an analog of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail added to resist breakdown. It is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the ACTH fragment without the parent hormone's cortisol-raising activity. It is used clinically and registered in Russia (including for ischemic stroke and cognitive disorders) but is not approved by the FDA or EMA, and Western evidence is limited.
Also: NAP, AL-108
Davunetide (NAP) is an eight-amino-acid fragment (NAPVSIPQ) of activity-dependent neuroprotective protein (ADNP), discovered at Tel Aviv University and given as a nasal spray. It was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. Its big test, a phase 2/3 trial in progressive supranuclear palsy (PSP), failed cleanly in 2012, and development stalled. It has since been revived by its inventors, who argue it works in women and are pursuing ADNP syndrome, but those claims rest on reanalyses of old data, not a new successful trial.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Semax | Davunetide |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semax is derived from ACTH(4-10) but, unlike ACTH, does not stimulate the adrenal or cortisol axis; its main documented action is upregulating brain-derived neurotrophic factor (BDNF) and its receptor TrkB, especially in the hippocampus. In rats, a single dose increases BDNF protein and mRNA and raises TrkB phosphorylation, activating growth and survival pathways (such as MAPK/ERK and PI3K/Akt) that support neuron health and plasticity. It also modulates dopamine and serotonin signaling and influences genes tied to the immune and vascular response after brain ischemia. The combined effect in animal models is neuroprotection against insults like reduced blood flow and oxidative stress, plus enhanced learning and memory. The Pro-Gly-Pro extension makes it more stable than the bare ACTH(4-10) sequence, which is partly why it stays active intranasally. | NAP comes from ADNP, a protein essential for brain development. In cell and animal studies it interacts with microtubule end-binding proteins (EB1 and EB3), promoting microtubule stability and reducing tau phosphorylation, which is why it was aimed at tauopathies like PSP and Alzheimer's disease. Mutations in the ADNP gene itself cause ADNP syndrome (Helsmoortel-Van der Aa syndrome), and in ADNP-deficient mice NAP improved some behavioral and neural measures, the rationale for that newer program. The PSP trial did not include target-engagement measures, so it never showed the drug was actually doing this in human brains. |
| Common Dosing | 200-600 mcg daily 1-3x daily | 30 mg intranasal twice daily (PSP trial dose) Once or twice daily |
| Administration | Intranasal spray (most common) | Intranasal spray (an IV form, AL-208, was tested in cardiac surgery) |
| Typical Duration | 10-30 days typical | 12 weeks to 52 weeks in trials |
| Best Time to Take | Morning or early afternoon | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The mechanistic core is well documented preclinically: Dolotov et al. (2006, Brain Research) showed a single intranasal Semax dose raised hippocampal BDNF protein, TrkB phosphorylation, and BDNF and TrkB mRNA in rats, alongside improved learned behavior. Additional rat work shows neuroprotection and changes in immune- and vascular-related gene expression after experimental stroke. Human clinical use is real but the published trials are mostly Russian-language, small, and frequently non-randomized or open-label: studies in acute ischemic-stroke patients reported faster recovery of neurological function, and a 2018 study reported increased plasma BDNF with improvements on disability and motor scales. These results are promising but methodologically weaker than Western regulatory-grade trials and have not been replicated in large independent Western studies. Honest summary: solid animal mechanistic data and decades of Russian clinical use, but the human cognitive and stroke claims rest on small, mostly non-randomized studies and are not validated by FDA or EMA-grade trials. | The headline result is negative. In the phase 2/3 PSP trial (Boxer and colleagues, Lancet Neurology 2014), 313 patients got 30 mg intranasal davunetide twice daily or placebo for 52 weeks. Disease progression was identical in both groups on both primary measures (PSP Rating Scale and Schwab and England daily living scale), and the authors concluded davunetide is not an effective treatment for PSP. Earlier phase 2 work was mixed: a 12-week trial in 144 people with amnestic mild cognitive impairment hinted at working-memory benefits, and a schizophrenia trial missed one co-primary endpoint while hitting another. The original developer, Allon Therapeutics, stopped investing and was later absorbed by Paladin Labs. The revival comes from the inventor's group: post hoc reanalyses of the PSP data (Translational Psychiatry 2023, Molecular Psychiatry 2026) report that women declined faster than men and that davunetide slowed decline in women only. A similar sex-split reanalysis of the MCI trial was published in 2024. These findings are interesting but are subgroup analyses of trials that failed overall, done by researchers tied to the company now developing the drug (ExoNavis Therapeutics), so they need a new prospective trial to mean much. ExoNavis has said a phase 3 in children with ADNP syndrome began in 2024, but Alzforum could not find it in trial registries. Davunetide holds FDA orphan and rare pediatric disease designations and EMA orphan status for ADNP syndrome. |
Frequently Asked Questions: Semax vs Davunetide
What is the difference between Semax and Davunetide?
Semax is a cognitive peptide that semax is a synthetic heptapeptide (met-glu-his-phe-pro-gly-pro) developed in russia in the 1980s as an analog of the acth(4-10) fragment, with a pro-gly-pro tail added to resist breakdown. it is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the acth fragment without the parent hormone's cortisol-raising activity. it is used clinically and registered in russia (including for ischemic stroke and cognitive disorders) but is not approved by the fda or ema, and western evidence is limited. Davunetide is a cognitive peptide that davunetide (nap) is an eight-amino-acid fragment (napvsipq) of activity-dependent neuroprotective protein (adnp), discovered at tel aviv university and given as a nasal spray. it was meant to protect brain cells by stabilizing microtubules, the scaffolding that tau normally supports. its big test, a phase 2/3 trial in progressive supranuclear palsy (psp), failed cleanly in 2012, and development stalled. it has since been revived by its inventors, who argue it works in women and are pursuing adnp syndrome, but those claims rest on reanalyses of old data, not a new successful trial. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semax or Davunetide?
Neither is universally "better" - the choice depends on your specific goals. Semax is typically used for cognitive purposes, while Davunetide is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semax and Davunetide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semax and Davunetide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.